Abstract
Introduction
Recently, we reported 3 elderly patients with reduced circulating levels of aldosterone, despite the mineralocorticoid excess state (1, 2) . They responded to blockade of mineralocorticoid receptor, and, therefore, their abnormalities were similar to those seen in the syndrome of apparent mineralocorticoid excess (AME), caused by mutations of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) gene (3, 4) . As these patients with an AME-like condition had no history of juvenile hypertension, their abnormalities might be due to the acquired impairment of the enzyme. Moreover, since spironolactone was used as a first choice drug in improving hypertension as well as hypopotassemia in these patients, in the present paper, we propose the name spironolactone effective hypertension in the elderly (SEHE) to describe this new entity. (5) . Moreover, recent studies have described that the syndrome of AME (6) or SEHE (1, 7) was also characterized by a high serum cortisol to cortisone ratio. However, there were only a few reports that use the serum cortisol to cortisone ratio as a marker of 11β-HSD2 activity, especially in SEHE.
Because of the prolonged serum half-life of cortisol, the ratio of the sum of 24-hour urine tetrahydrocortisol (THF) and allo-THF excretions to 24-hour urine tetrahydrocortisone (THE) excretion has been considered to be an important parameter of enzyme activity (4). In addition to this precursor-product ratio, it has been previously demonstrated that measurements of cortisol and cortisone exretions in urine provide the most sensitive index of 11β-HSD2 activity
In the present paper, we describe 2 patients with SEHE. Furthermore, we review 5 cases, including 3 cases reported previously in detail by us (1, 2) and assess the usefulness of determining the serum cortisol to cortisone ratio as a marker of 11β-HSD2 activity.
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Hormone assays
Twenty-four-hour total cortisol, total cortisone, THF, allo-THF and THE excretions were determined in Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan, by urinary steroid profile analysis, using gas chromatography/mass spectrometry in selected ion monitoring (GCMS-SIM), as described previously in detail (8)
.
Discussion
There are two isozymes of 11β-HSD, type 1 and 2 (4).
The type 1 isozyme is located mainly in the liver and adipose tissues, which are abundant in glucocorticoid receptor, and catalyzes mainly the conversion of inactive cortisone to active cortisol. A recent study (9) demonstrated that, from the striking phenotype of the transgenic animal (10, 11) , obesity and metabolic syndrome are closely related to the enhancement of this enzyme. Moreover, they found a significant relation between BMI and 11β-HSD 1 activity or mRNA in subcutaneous adipose tissue from healthy volunteers (9 
